Researchers at The Jackson Laboratory employed genetically diverse Collaborative Cross mice to dissect how inherited variability affects tumor response to immune checkpoint inhibitors. Their findings demonstrated gene-specific effects on therapeutic outcomes, highlighting the limitations of genetically uniform models. This work advances understanding of patient-specific cancer therapy responses and could inform precision immunotherapy strategies.